Cardurion Pharma, a developer of cardiovascular therapeutics, is dedicated to addressing cardiovascular diseases. The company's advanced and innovative therapeutics provide new treatment mechanisms for heart diseases that contribute to morbidity and mortality. This enables healthcare professionals to effectively prevent arrhythmia disorders and heart failures.
Deepwork Capital, Digitalis Ventures, Bain Capital, Polaris Partners, Ascenta Capital, Farallon Capital Management, Millennium Management, Kenneth Novack, The Invus Group, Bain Capital Life Sciences, Takeda Pharmaceutical Company, GV, Delos Capital, DHS Ventures & Holdings, Fidelity Management & Research, Blue Owl Capital.